Xeris Biopharma Holdings (XERS) Net Cash Flow Growth (3y) (2023 - 2026)
Xeris Biopharma Holdings (XERS) Net Cash Flow Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -28.90% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -5.41% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 19.55% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 95.24% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -106.21% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 4.40% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 17.73% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 60.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.19% |
| Mar 31, 2026 | 26.20% |
| Dec 31, 2025 | -22.77% |
| Sep 30, 2025 | 69.48% |
| Jun 30, 2025 | 28.06% |
| Mar 31, 2025 | -33.16% |
| Dec 31, 2024 | 16.77% |
| Sep 30, 2024 | 33.36% |
| Jun 30, 2024 | -19.16% |
| Mar 31, 2024 | -29.35% |
| Dec 31, 2023 | 319.43% |